Valuation: Alligator Bioscience AB

Market Cap 26.88M 2.82M 2.45M 2.28M 2.09M 3.95M 269M 4.02M 10.55M 134M 10.59M 10.35M 449M P/E 2026 *
-
P/E 2027 * -
Enterprise Value 26.88M 2.82M 2.45M 2.28M 2.09M 3.95M 269M 4.02M 10.55M 134M 10.59M 10.35M 449M EV / Sales 2026 *
0.67x
EV / Sales 2027 * 4.56x
Free-Float
75.08%
Yield 2026 *
-
Yield 2027 * -
1 week 0
Extreme 0.0001
0
1 month 0
Extreme 0.0001
0.04
Current year 0
Extreme 0.0001
0.07
1 year 0
Extreme 0.0001
0.5
3 years 0
Extreme 0.0001
131.6
5 years 0
Extreme 0.0001
640
10 years 0
Extreme 0.0001
3,715
Manager TitleAgeSince
Chief Executive Officer 55 2021-05-31
Director of Finance/CFO 61 2024-08-11
Chief Tech/Sci/R&D Officer - 2025-03-31
Director TitleAgeSince
Chairman 55 -
Director/Board Member 64 2021-05-31
Director/Board Member 68 2022-05-08
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 2.82M
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+411.96%+495.33% 39.87B
-1.16%+12.96%+28.81%+7.25% 38.68B
-1.88%-3.03%+5.69%+53.00% 35.13B
-1.74%+5.12%+14.44%+41.77% 29.79B
-0.21%-4.04%+36.40%+125.75% 16.11B
-2.85%-3.92% - - 16.08B
-0.64%+2.65%+3.40%+13.11% 13.61B
-1.19%-1.32%-1.73%-34.37% 12.62B
Average -1.35%+1.05%+62.16%+89.14% 27.82B
Weighted average by Cap. -1.60%+2.03%+79.78%+108.61%

Financials

2026 *2027 *
Net sales 39.9M 4.18M 3.64M 3.38M 3.11M 5.87M 399M 5.96M 15.66M 199M 15.71M 15.37M 667M 5.9M 619K 538K 501K 460K 868K 59.05M 881K 2.32M 29.4M 2.32M 2.27M 98.58M
Net income -36.3M -3.81M -3.31M -3.08M -2.83M -5.34M -363M -5.42M -14.25M -181M -14.29M -13.98M -607M -69.9M -7.33M -6.37M -5.93M -5.44M -10.28M -700M -10.44M -27.43M -348M -27.52M -26.92M -1.17B
Net Debt - -
Logo Alligator Bioscience AB
Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.
Employees
11
Date Price Change
26-07-31 €0.000100 -.--%
26-07-30 €0.000100 -.--%
26-07-29 €0.000100 -.--%
26-07-28 €0.000100 -.--%
26-07-27 €0.000100 -.--%
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise